搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Cure Today
2 小时
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West ...
Cure Today
1 天
Rybrevant Plus Chemo Approved by FDA in Lung Cancer Subset
The FDA has approved Rybrevant plus chemotherapy in certain patients with locally advanced or metastatic non-small cell lung ...
Cure Today
11 小时
Navigating the ‘Ever-Evolving Trajectory’ of Metastatic Breast Cancer
Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...
Cure Today
1 天
How Cancer Bracelets Can Help Spread Awareness
I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to ...
Cure Today
15 小时
Infections May Impact Survival, Quality of Life in Patients With MDS
While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...
Cure Today
1 天
Trodelvy May Improve Responses in Bladder Cancer Subtype
Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...
Cure Today
1 天
Why Transfusion Independence Matters for Patients With MDS
Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...
Cure Today
1 天
Patients With Lower-Risk Myelofibrosis May Respond to Jakafi
Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...
Cure Today
2 天
Healing and Reflecting on My Ovarian Cancer Experience
The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing ...
Cure Today
1 天
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
Cure Today
2 天
FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...
Cure Today
2 天
Treatment Switching May Be Less Likely With Brukinsa vs Other BTK Inhibitors in CLL/SLL
Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈